This study is in progress, not accepting new patients
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Vadim Koshkin
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Vadim Koshkin
I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Nektar Therapeutics
- ID
- NCT03785925
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated